OCULAR THERAPEUTIX, INC Retained Earnings
OCULAR THERAPEUTIX, INC (OCUL) had Retained Earnings of -$1.32 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-03
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.32B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.25B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.16B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.09B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.32B 10-Q · filed 2026-08-03 |
| 2026-03-31 | -$1.25B 10-Q · filed 2026-05-05 |
| 2025-12-31 | -$1.16B 10-Q · filed 2026-08-03 |
| 2025-09-30 | -$1.09B 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$1.02B 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$955.14M 10-Q · filed 2025-05-05 |
| 2024-12-31 | -$891.08M 10-K · filed 2026-02-05 |
| 2024-09-30 | -$842.70M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$806.20M 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$762.43M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$697.58M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$668.36M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$667.84M 10-Q · filed 2023-08-07 |
| 2023-03-31 | -$647.16M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$616.84M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$601.30M 10-Q · filed 2022-11-07 |
| 2022-06-30 | -$577.11M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$558.35M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$545.80M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$541.95M 10-Q · filed 2021-11-08 |
| 2021-06-30 | -$544.61M 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$536.13M 10-Q · filed 2021-05-05 |
| 2020-12-31 | -$539.25M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$453.64M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$441.69M 10-Q · filed 2020-08-07 |
| 2020-03-31 | -$405.13M 10-Q · filed 2020-05-08 |
| 2019-12-31 | -$383.62M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$357.60M 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$338.82M 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$314.37M 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$297.24M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$279.84M 10-Q · filed 2018-11-07 |
| 2018-06-30 | -$264.83M 10-Q · filed 2018-08-07 |
| 2018-03-31 | -$251.03M 10-Q · filed 2018-05-08 |
| 2017-12-31 | -$237.26M 10-K · filed 2019-03-07 |
| 2017-09-30 | -$224.16M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$208.60M 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$189.90M 10-Q · filed 2017-05-05 |
| 2016-12-31 | -$173.88M 10-K · filed 2018-03-08 |
| 2016-09-30 | -$161.06M 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$151.46M 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$140.02M 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$129.18M 10-K · filed 2017-03-10 |
| 2015-09-30 | -$118.54M 10-Q · filed 2015-11-10 |
| 2015-06-30 | -$107.02M 10-Q · filed 2015-08-10 |
| 2015-03-31 | -$97.01M 10-Q · filed 2015-05-15 |
| 2014-12-31 | -$89.43M 10-K · filed 2016-03-10 |
| 2014-09-30 | -$81.47M 10-Q · filed 2014-11-12 |
| 2014-06-30 | -$74.18M 10-Q · filed 2014-08-29 |
| 2013-12-31 | -$60.78M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |